Humana (NYSE:HUM) Rating Lowered to Sell at ValuEngine

Humana (NYSE:HUM) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report released on Wednesday, ValuEngine reports.

HUM has been the subject of several other reports. Piper Jaffray Companies upped their price objective on Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Cantor Fitzgerald raised Humana from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $300.00 to $345.00 in a research report on Monday, August 12th. UBS Group lifted their target price on Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. SunTrust Banks boosted their target price on Humana to $340.00 and gave the company a “hold” rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their price target on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the company. Humana presently has a consensus rating of “Buy” and an average target price of $341.95.

Humana stock traded down $0.04 during midday trading on Wednesday, hitting $276.81. 1,022,545 shares of the company’s stock were exchanged, compared to its average volume of 1,267,515. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The stock has a market cap of $37.24 billion, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 1.19 and a beta of 0.84. Humana has a 12-month low of $225.65 and a 12-month high of $355.88. The firm’s 50 day simple moving average is $287.14 and its 200 day simple moving average is $269.38.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, beating analysts’ consensus estimates of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same period in the prior year, the company earned $3.96 earnings per share. The business’s revenue was up 13.9% compared to the same quarter last year. On average, equities research analysts forecast that Humana will post 17.63 EPS for the current fiscal year.

In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.54% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Humana by 8.3% during the 4th quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock worth $507,198,000 after purchasing an additional 135,776 shares in the last quarter. First Allied Advisory Services Inc. lifted its stake in shares of Humana by 7.8% in the first quarter. First Allied Advisory Services Inc. now owns 5,105 shares of the insurance provider’s stock valued at $1,365,000 after purchasing an additional 369 shares during the period. Toronto Dominion Bank boosted its holdings in Humana by 15.2% during the first quarter. Toronto Dominion Bank now owns 94,501 shares of the insurance provider’s stock worth $25,131,000 after buying an additional 12,502 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in Humana by 7.0% during the first quarter. CIBC Asset Management Inc now owns 16,627 shares of the insurance provider’s stock worth $4,423,000 after buying an additional 1,085 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its holdings in Humana by 77.6% during the first quarter. Moors & Cabot Inc. now owns 1,318 shares of the insurance provider’s stock worth $350,000 after buying an additional 576 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: Why do analysts give a neutral rating?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.